Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death

BACKGROUND: Empagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from glucose control, but its benefits on arrhythmogenesis and sudden cardiac death are n...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zhaoyang, Ju, Feng, Du, Lei, Abbott, Geoffrey W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491391/
https://www.ncbi.nlm.nih.gov/pubmed/34607570
http://dx.doi.org/10.1186/s12933-021-01392-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491391/
https://www.ncbi.nlm.nih.gov/pubmed/34607570
http://dx.doi.org/10.1186/s12933-021-01392-6

Ejemplares similares